New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
NCT ID NCT07570823
First seen May 12, 2026 · Last updated May 12, 2026
Summary
This phase 3 trial compares a new drug (SCTB35) plus chemotherapy against a standard drug (rituximab) plus chemotherapy in about 101 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the new combination works better at controlling the cancer and has an acceptable safety profile. Participants must be 18-80 and have had at least one prior treatment including an anti-CD20 antibody with chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
Conditions
Explore the condition pages connected to this study.